ROCKET PHARMACEUTICALS, INC. — fact timeline

ROCKET PHARMACEUTICALS, INC. completed a disposition involving a large pharmaceutical company for $180.0 million (closed 2026-06-10).

“Sale was completed pursuant to the terms of an asset purchase agreement, dated April 26, 2026 (the “PRV APA”). Pursuant to the PRV APA, the Company received gross proceeds of $180.0 million from the buyer upon the closing of the Asset Sale. The foregoing description of the PRV APA does not purport to be complete and is subject to, and qualified in its entirety, by”

ROCKET PHARMACEUTICALS, INC. shareholders approved Stock option exchange program at the 2026-05-20 meeting.

“Proposal Four – Stock Option Exchange Program The Company’s stockholders approved the proposed stock option exchange program as described in the 2026 Proxy Statement. The final votes were: Votes For Votes Against Abstentions Broker Non-Votes 45,582,445 17,615,213 86,486 17,490,515”

ROCKET PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-20 meeting.

“The final votes were: Votes For Votes Against Abstentions Broker Non-Votes 61,389,376 1,671,016 223,752 17,490,515”

ROCKET PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered accounting firm for fiscal year ending December 31, 2026 at the 2026-05-20 meeting.

“Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes: Votes For Votes Against Abstentions 79,195,009 1,002,656 576,994”

ROCKET PHARMACEUTICALS, INC. shareholders approved Election of seven directors to the Board at the 2026-05-20 meeting.

“The Company’s stockholders approved the election of seven directors to the Company’s Board of Directors (“Board”) by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Peter Fong, M.D. 62,067,824 1,216,320 17,490,515 Carsten Boess 62,711,345 572,799 17,490,515 Mikael Dolsten, M.D., Ph.D. 59,500,907 3,783,237 17,490,515 Fady Malik, M.D., Ph.D. 62,755,875 528,269 17,490,515 Gaurav Shah, M.D. 62,808,593 475,551 17,490,515 David P. Southwell 43,172,112 20,112,032 17,490,515 Roderick Wong, M.D. 62,699,331 584,813 17,490,515”

ROCKET PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: net income Net loss was $47.6 million or $0.42 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.42 per share (basic and diluted).

“Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ended March 31, 2026.”

ROCKET PHARMACEUTICALS, INC. entered into PRV APA valued at $180 million (effective 2026-04-26).

“On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).”

ROCKET PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC (effective 2026-03-10).

“Upon entry into the Sales Agreement, the Company terminated its prior “at-the-market” sales agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC, dated February 28, 2022, (the “Prior Sales Agreement”), as amended by Amendment No. 1 to the Prior Sales Agreement, dated as of September 12, 2023 (“Amendment No. 1”), pursuant to which the Company could offer and sell, from time to time through Cowen and Company, LLC, as its agent, shares of the Company’s common stock.”

ROCKET PHARMACEUTICALS, INC. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at $100,000,000 (effective 2026-03-10).

“On March 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $100,000,000 (the “Shares”), through the Sales Agent.”

ROCKET PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.5 million (approximately 30%).

“The Company began notifying affected employees on July 23, 2025, and expects the RIF to be completed by August 8, 2025. The Company estimates that it will incur approximately $3.5 million in restructuring and restructuring-related charges in the second half of 2025 in connection with the Plan, consisting primarily of employee severance payments and other”

R. Keith Woods departed as Director at ROCKET PHARMACEUTICALS, INC..

“On April 26, 2025, R. Keith Woods informed the board of directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”) that he has accepted a Chief Operating Officer position with a biopharmaceutical company and therefore has decided not to stand for re-election to the Board at the Company’s upcoming 2025 annual meeting (the “2025 Annual Meeting”).”

Sarbani Chaudhuri was appointed as Chief Commercial & Medical Affairs Officer at ROCKET PHARMACEUTICALS, INC..

“On April 7, 2025, Sarbani Chaudhuri was appointed by Rocket Pharmaceuticals, Inc. (the “Company”) as the Company’s Chief Commercial & Medical Affairs Officer.”

Piratip Pratumsuwan was appointed as Director at ROCKET PHARMACEUTICALS, INC..

“On January 25, 2025, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Piratip Pratumsuwan to the Board, effective January 27, 2025.”

Naveen Yalamanchi resigned as Director at ROCKET PHARMACEUTICALS, INC..

“On January 25, 2025, Naveen Yalamanchi resigned from the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”), effectively immediately.”

Dr. Mikael Dolsten was appointed as Director at ROCKET PHARMACEUTICALS, INC..

“appointed Dr. Mikael Dolsten, M.D., Ph.D. to the Board, effective September 9, 2024.”

ROCKET PHARMACEUTICALS, INC. reported preliminary financial results for the quarter ended March 31, 2024.

“On May 6, 2024, Rocket Pharmaceuticals, Inc. (the “Company”) announced certain preliminary financial information for the quarter ended March 31, 2024.”

Aaron Ondrey was appointed as Chief Financial Officer at ROCKET PHARMACEUTICALS, INC..

“On March 25, 2024, Aaron Ondrey was appointed by Rocket Pharmaceuticals, Inc. (the “Company”) as the Company’s Chief Financial Officer and Principal Financial Officer.”

ROCKET PHARMACEUTICALS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss was $59.7 million and $245.6 million or $0.64 and $2.92 per share (basic and diluted) for the three and twelve, EPS $0.64 and $2.92 per share (basic and diluted) for the three and twelve months ended December 31, 2023.

“Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress”

R. Keith Woods was appointed as Director at ROCKET PHARMACEUTICALS, INC..

“appointed R. Keith Woods to the Board, effective December 7, 2023.”

ROCKET PHARMACEUTICALS, INC. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC (effective 2023-09-12).

“On September 12, 2023, Rocket Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to (i) 7,812,500 shares of common stock (the “Shares”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 3,126,955 shares of common stock (the “Offering”).”

ROCKET PHARMACEUTICALS, INC. amended Sales Agreement with Cowen and Company, LLC valued at $180,000,000 (effective 2023-09-12).

“(the “ Company ”) entered into a sales agreement (the “ Sales Agreement ”) with Cowen and Company, LLC (“ Cowen ”) pursuant to which the Company may, from time to time, sell shares of its common stock, par value $0.01 per”

ROCKET PHARMACEUTICALS, INC. shareholders approved Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2023-06-22 meeting.

“The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement for the 2023 Annual Meeting of Stockholders pursuant to Section 14A of the Exchange Act, including the Compensation Discussion and Analysis, the Summary Compensation Table, and the narrative disclosures that accompany the compensation tables. The final votes were:”

ROCKET PHARMACEUTICALS, INC. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2023-06-22 meeting.

“The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023 by the following votes:”

ROCKET PHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2023-06-22 meeting.

“The Company’s stockholders approved the election of nine directors to the Company’s Board of Directors (“Board”) by the following votes:”

Mark White was appointed as Chief Medical Officer at ROCKET PHARMACEUTICALS, INC..

“Additionally, on April 4, 2023, Mark White joined the Company as its new Chief Medical Officer.”

Jonathan Schwartz changed role as Chief Gene Therapy Officer at ROCKET PHARMACEUTICALS, INC..

“On April 4, 2023, Jonathan Schwartz transitioned from Chief Medical Officer of Rocket Pharmaceuticals, Inc. (the “ Company ”) to Chief Gene Therapy Officer,”

ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.

“On February 27, 2023, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022.”

ROCKET PHARMACEUTICALS, INC. shareholders approved To approve the issuance of Parent Shares to security holders of Renovacor, as contemplated by the Merger Agreement pursuant to Nasdaq Rule 5635(a)(2) at the 2022-11-30 meeting.

“Rocket Share Issuance Proposal . To vote to approve the issuance of Parent Shares to security holders of Renovacor, as contemplated by the Merger Agreement pursuant to Nasdaq Rule 5635(a)(2) (the “Rocket Share Issuance Proposal”). Votes For Votes Against Abstentions 58,919,928 45,017 51,950”

ROCKET PHARMACEUTICALS, INC. completed an acquisition involving Renovacor, Inc. (closed 2022-12-01).

“On December 1, 2022, pursuant to the terms of the Merger Agreement, (i) Merger Sub I merged with and into the Company (the “First Merger”) and (ii) the Company, as the surviving company of the First Merger, merged with and into Merger Sub II (the “Second Merger” and together with the First Merger, the “Mergers”), with Merger Sub II surviving the Mergers.”

ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter ended September 30, 2022.

“On November 3, 2022, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022.”

John Militello was appointed as Interim Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..

“John Militello, the Company’s Vice President – Finance, Senior Controller, Treasurer and Principal Accounting Officer, was appointed as the interim Principal Financial Officer of the Company, as of the effective date of Mr. Garcia-Parada’s resignation.”

Carlos Garcia-Parada resigned as Chief Financial Officer and Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..

“Carlos Garcia-Parada tendered his resignation as Chief Financial Officer and Principal Financial Officer of the Company, effective March 16, 2022, due to personal reasons.”

Fady Malik was appointed as Director at ROCKET PHARMACEUTICALS, INC..

“appointed Fady Malik, M.D., Ph.D., to the Board, effective March 10, 2022.”